935-34 Special Considerations for Diabetics Receiving Platelet IIb/IIIa Antagonists During Coronary Interventions: Results from the EPIC Trialart  by Moliterno, David J. et al.
JACC February 1995 ABSTRAcrS 155A
tMLD ,j,MLD, but OS <0.5 ,j,MLD and OS ,,::05 P
(N ~ 14) (N ~ 44) IN ~ 79)
performed on an Evolution Tomograph (Siemens) with 100 msec scans (flow
mode. 0% RR-trigger. scan begin at one half of the circulation time). In 17
patients (15 males/2 females) 59 ± 6 years) all stents could clearly be identi-
fied and distinguished from adjacent calcium deposits by EBT. Additionally.
stent patency was assessed using contrast medium (30 ml bolus injection
at 10 mils) in 8 patients. In all patients contrast medium opacification of the
coronary vessel distal to the stent indicated stent patency. In four cases this
result was verified angiographically.
Conclusion: In contrast to coronary angiography. EBT allows to exactly lo-
calize intracoronary stents and control their position noninvasively. With con-
trast medium application. it is a simple noninvasive method to prove stent
patency.
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Angiographically Complex Lesions are
Associated with Increased Levels of Thrombin
Generation and ActiVity Following PTCA
Coagulation Lesion Pre Post 10 Min
Marker Morphology PTCA PTCA
FPA Complex 2.1 (16-35)' 3.3 (2.6-58)1t
ng/ml Simple 1.9 (1.3-3.9) 2.1 (15-9.8)
Fl + 2 Complex 0.65 (054-1.04)' 07610.84-1.03)-
nmollL Simple 0.84 (053-0.77) 061 (0.48-1.08)
Prior studies in diabetic patients have demonstrated heightened coagulabil-
ity and platelet aggregability. Likewise. patients with diabetes are known to
have an increased rate of restenosis following balloon angioplasty. With po-
tent platelet inhibitors. such as the monoclonal antibody c7E3. both immedi-
ate and late adverse events have been shown to decrease in high-risk angio-
plasty. In the EPIC (Evaluation of c7E3 Fab in Prevention of Ischemic Com-
plications) Trial. we enrolled 50612099 (24%) patients with diabetes equally
to placebo. c7E3 as bolus alone. or c7E3 as bolus and infusion. At 6-month
follow-up. clinical restenosis (death. MI. or target vessel revascularization)
was assessed. Patients with diabetes who received placebo had the highest
(40%) restenosis (figure). Patients with diabetes but who received c7E3 as
Geometric remodeling correlated with tissue growth (r 0.426. p <
0.0001), but was independent of device used. We conclude: Patterns of the
late arterial response following coronary intervention are determined less by
tissue growth than by the direction and magnitude of geometric remodel-
ing.Lilte lumen gain is the result of "overcompensation" with an increase in
EEM area and minimal tissue growth. Lilte lumen loss without angiographic
restenosis is the result of modest tissue growth with no decrease in EEM
area. Angiographic restenosis is associated with moderate tissue growth.
but is predominantly the result of geometric remodeling; a decrease in EEM
area accounts for 66% of late lumen area loss.
Jonathan D. Marmur. Samin K. Sharma. Niki E. Kantrowitz, Vanita Gupta.
Thomas Cocke. Srinivas Duwuri, John A. Ambrose. Mt. Sinai School of Medicine.
New York. NY
Angiographically complex coronary lesions (irregular borders. overhanging
edges. or filling defects) are associated with unstable coronary syndromes
and an increased incidence of thrombosis following coronary angioplasty
(PTCA). To study the relationship between angiographic lesion morphology
and activation of the coagulation cascade. we measured coronary plasma
levels of FPA and Fl + 2 in a series of patients undergoing PTCA. Samples
were withdrawn through a coronary sampling catheter placed proximal to
the lesion prior to PTCA (Pre-PTCA) and placed distal to the lesion 10 min
after the final balloon inflation (Post-PTCA). Angiographic interpretations of
lesion complexity were made without knowledge of the plasma FPA and Fl
+ 2 levels.
Results: Plasma FPA and Fl + 2 levels measured in 50 patients are shown
below in median (95% confidence intervals). Twenty-four (48%) of the pa-
tients had a complex lesion morphology.
Although pre-PTCA FPA and Fl + 2 values were similar for simple and
complex lesions. post-PTCA FPA and Fl + 2 values increased only for com-
plex lesions. Thus. complex lesions are associated with increased thrombin
generation and activity. This may playa role in the thrombotic and restenotic
complications associated with percutaneous treatment of complex coronary
lesions.
Special Considerations for Diabetics Receiving
Platelet lib/ilia Antagonists During Coronary
Interventions: Results from the EPIC Trial
David J. Mollterno. Robert M. Califf. Keavin Anderson. Harlan F. Weisman. Eric
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Rebulking After Directional Atherectomy
Compared with Balloon Angioplasty: Quantitative
Lesion Morphology
Peter H. Seidelin, Eric A. Cohen, Valter C. Lima, Brian P. Kimball, Allan G. Adelman,
CCAT Investigators. Mount Sinai and The Toronto Hospital. Toronto. Ontario. Canada
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Differing Mechanisms of Late Arterial Responses
to Transcatheter Therapy: A Serial Quantitative
Angiographic and Intravascular Ultrasound Study
Gary S. Mintz, Jeffrey J. Popma. Augusto D. Pichard. Kenneth M. Kent, Lowell
F. Satler, Theresa A. Bucher, Carol L. Walsh. Jennifer Gnffin, Martin B. Leon.
Washington Hospital Center, Washington. DC
We have previously shown that the proportional loss in minimum lumen di-
ameter (MLD) after directional atherectomy (DCA) is greater than after bal-
loon angioplasty (BA). To examine whether other parameters of lesion mor-
phology show the same increase in loss with DCA. we analyzed the post-
procedure and 6 month follow-up angiograms in 228 patients randomized to
DCA or BA in the Canadian Coronary Atherectomy Trial (CCAT) in whom no
crossover between procedures occurred. Initial gain and late loss in MLD.
initial reduction (red) and late increase (Inc) in lesion length (LL) and initial
"debulk" and late "rebulk" in plaque area (PA) were compared by procedure.
Mean values (±sem). measured by automatic interpolative quantitative coro-
nary analysis (CMS) are given:
DCA (111) 1.47 ± 0.040.81 ± 0.06 675 ± 0.47 5.58 ± 0.61 102 ± 05368 ± 0.71
SA (117) 115±0.04 0.41 ±0.05 4.69 ± 0.47 2.80±0.51 87±0593.9±67
'P < 0.001. "P < 0.01, tp < 0.05
Clinical Observations on Restenosis
Compared to BA, DCA produced a significantly ('P < 0.001, "P < 0.01.
tP < 0.05) larger increase in MLD and decrease in both LL and PA (from
pre- to post-procedure). However. this was offset by a greater late loss in
MLD and increase in LL and PA (P values as above from post- to follow-up
procedure). Resultant net changes (from pre- to follow up procedure) were
not different. These results confirm that DCA more effectively "debulks" le-
sions. DCA. however. was associated with more "rebulking" in the follow-up
period. so that the net results on quantitative lesion morphology of the two
interventions were the same. These findings are consistent regardless of the
quantitative angiographic parameter examined.
Conclusions: DCA appears to have a device specific effect on the
restenotic process which is probably related to the amount of vessel wall
injury associated with this procedure.
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To evaluate the mechanisms of late arterial response to transcatheter ther-
apy, we analyzed serial quantitative angiographic minimum lumen diameter
(MLD) and diameter stenosis (DS) and intravascular ultrasound external elas-
tic membrane (EEM). lumen. and plaque area in 137 lesions treated with var-
ious devices (31 PTCA. 57 directional and 26 rotational atherectomy. and 23
excimer laser angioplasty). From serial angiography (post-intervention and at
follow-up 4.7 ± 2.8 mos later), lesions were divided into 3 groups based on
t:J. MLD and follow-up %DS. From serial intravascular ultrasound. late lumen
loss (t:J.lumen area), geometric remodeling (t:J.EEM area). and tissue growth
(t:J.plaque area) were calculated for each group:
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bolus and infusion had a 36% rate of clinical restenosis (CR). Patients with-
out diabetes had a lower rate of restenosis whether receiving placebo ICR
~ 33%) or c7E3 (CR = 24%). In regression analysis. diabetes was the only
baseline clinical feature associated with an increased event rate (hazard ratio
1.44. P = 0.001). Among patients without diabetes. the relative risk of major
bleeding events was 2.6 times higher for those receiving c7E3 compared
to placebo 19.9% vs. 3.7%. respectively). This effect was doubled among
diabetics (12.9% vs. 2.2%, relative risk = 5.8). In conclusion, these data im-
portantly confirm the higher clinical restenosis among diabetics and demon-
strate a marked propensityto major bleeding events among diabetics treated
with potent platelet antagonists.
50.,- ...,
ing In = 21) and prolonged perfusion balloon inflation (PPB; n = 22) as initial
bail-out therapy in failed PTCA. Core lab qualitative and quantitative angiog-
raphy analysis was possible in 40/43 patients.
Results.
Pre randomisation Post Randomisation
MLD{mm) % MLD(mm) % Success Recoil (mm)
5tent 1.1 ± 05 59 ± 17 2.2 ± 0.4 20 + 11 90% 032 ± 035
n ~ 21 19/21
PPB 12 ± 06 60 ± 18 1.5 ± 0.3 46 + 23 42% 096 ± 054
n ~ 19 8/19
P ns ns <0.001 <0.001 0002 <0.001
~ 40!-
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1) Stenting was more effective as bail-out therapy (90% vs 42% P < 0.002),
especially in treating dissections of grade C or above: stent 11/12 (91%) vs
PBB (0/5 (0)% P < 0.0001).
2) Angiographic results with successful PPB were inferior to stenting: %
stenosis: 30.6 ± 20.2; MLD 1.9 ± 0.3 (p < 0.05 cf stent MLD) due to greater
recoil in the PPB group: PPB 0.66 ± 0.34 mm Ip < 0.05 cf stent recoil).
3) Stenting following failed PPB was successful in 9/10 attempts with equiv-
alent angiograms results to primary stent bail-out: % stenosis 24.8 ± 8.2;
MLD 2.5 ± 0.4 mm. but procedure time was longer 152.6 ± 53.0 mins v
114.8 ± 31.3 mins (p < 0.05).
Summary. This randomised multicentre study of bailout therapy in failed
PTCA confirms the benefit of stenting in improving immediate results by re-
ducing elastic recoil and sealing complex dissections. Crossover to stenting
following failed PPB gives angiographic results comparable to primary bail-
out stenting at the expense of increased lab time.
AG Results Reference (mm) MLD(mm) % Stenosis
Baseline 3.11 ± 0.47 0.66 ± 0.58 79 ± 19
Post 5tent 309 ± 0.50 3.01 ± 0.47 3 ± 12
Follow Up 3.01 ± 0.48 1.80 ± 0.91 40 ± 28
Simon G. Ray. Ian M. Penn. Donald R. Ricci. Jacques Barth, G.B. John Mancini.
Christopher E. Buller. Blair O'Neill. Christopher Foster. David Almond.
Charles Lazzam. Louis Roy, Gerald Barbeau. Vancouver Hospital and Health Sciences
Centre. Bri~sh Columbia, Canada
TASC II is a randomised multicentre study comparing the strategies of stent-
There was 1 acute stent thrombosis event (1.2%). Restenosis by 50% di-
ameter stenosis criteria was present in 17 of 49 lesions (35%) and 13 of 39
patients (34%).
Conclusions. (1) Stent Implantation in diffuse disease that is assisted by
IVUS is associated with acceptable procedure complication rate and a low
stent thrombosis rate despite the absence of post stent anticoagulation in
the majority of patients. (2) The restenosis rate of 35% appears to represent
an improvement over the reported restenosis rates for diffuse disease after
angioplasty or other devices.
Restenosis After Coronary Angioplasty is
Associated with the Activation Status of
Circulating Phagocytes Before Treatment
De novo Restenosis Total
5 (76) PTCA (73) 5 (61) PTCA (60) 5 {137} PTCA(133)
Death O{O%) 1 a a 0 1
MI 7 1 3 0 10 1
CABG 2 1 0 2 2 3
Repeat
Interven 3 5 5 4 10
Event free
Survival 64 (84%) 65189%) 57 (93%) 53(88%) 121 (88%) 118{89%)
The Trial of Angioplasty and Stents in Canada:
Clinical Outcome
Ian M. Penn, Robert I. Brown. Donald R. Ricci. David Almond. Jean F. Marquis.
John Webb. Blair O·Neili. Brendon Foley. Cindy Wong, Stephanie Monkman. TASC
Investigators. University of British Columbia, Vancouve" B.C., Canada
The trial of angioplasty and stents in Canada (TASC I) compared the strategy
of coronary artery stenting (S) to PTCA in de novo (de N ~ 149) and restenosis
(R ~ 121) lesions with a l' end point of angiographic restenosis and 2' end
point of event free survival at 6 months.
Results:
There was a reduction of clinical events in patients with restenosis le-
sions treated by stenting as compared to de novo lesions: 6.6% vs 15.8%
P ~ 0.094. There was an increased early (less < 40 days) infarct rate in the
stented patients due to stent thrombosis and a trend towards decreased
intervention in target lesions at 6 months (p = 0.088).
Conclusion: The strategies of coronary artery stenting in this study had
equivalent of event free survival to STRESS and Benestent in de novo lesions.
Patients who underwent stenting for restenosis lesions had an improved out-
come with only a 7% cardiac event rate at 6 months.
Patrick W 5erruys, Anneke Pietersma. Marcel Kofflard, L. Elly A. de Wit.
Thea Stijnen, Johan F. Koster, Wim Sluiter. Erasmus University. Rotterdam, NL
Background. The purpose of this study was to identify biological risk factors
for restenosis after PTCA. in order to predict the long-term outcome of PTCA
before treatment.
Methods and Results. To investigate whether blood granulocytes and
monocytes could determine luminal renarrowing after PTCA. several char-
acteristics of these phagocytes were assessed before angioplasty in 32 pa-
tients who underwent PTCA of one coronary artery and who had repeat an-
giograms at six months follow-up. The plasma levels 1L-1 p, TNF-a, IL-6. fib-
rinogen. C-reactive protein and LP(a) before angioplasty were assessed as
well. We found that the expression of the membrane antigens CD64. CD66
and CD67 by granulocytes was inversely associated with the luminal renar-
rowing normalized for vessel size (relative loss) at six months after PTCA.
while the production of IL-1 p by stimulated monocytes was positively asso-
ciated with the relative loss. Next. these univariate predictors were corrected
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Results of Stent Implantation for Diffuse Coronary
Disease Assisted by Intravascular Ultrasound
Mechanism of Benefit of Stenting in Failed PTCA.
Final Results from the Trial of Angioplasty and
Stents In Canada (TASC II)
Luigi Maiello. Patrick Hall. Shigeru Nakamura. Simonetta Blengino. Leo Finci.
Giovanni Martini. Antonio Colombo. Columbus Hospital, Milan. Italy
The long term benefit of elective Palmaz-Schatz stent implantation for fo-
cal lesions in large vessels has been clearly delineated. The elective use of
stents in diffuse disease. however, has not been fully evaluated. This study
reports on the use of stents in 89 pts with 108 lesions (lesl with diffuse dis-
ease. Diffuse disease was defined as a lesion length longer than 20 mm. Af-
ter a successful angiographic result was obtained. intravascular ultrasound
(IVUS) was performed to confirm optimal stent expansion and lesion cover-
age and to guide further balloon dilation and stent implantation. The mean
age was 57 ± 10. Mean lesion length was 32 ± 6 mm. Vessel distribution was
51 LAD (47%). 45 RCA (42%). 10 LCX (9%). and 2 vein graft(2%) Lesion loca-
tion was 49 proximal (45%).52 mid (48%), and 7 distal 17%). 274 stents were
implanted (139 Palmaz-Schatz, 34 short (7 mm) Palmaz-Schatz, 48 Gianturco-
Roubin, and 53 Wiktor) for an average of 2.4 ± 1.4 stentsllesion. Procedure
success was achieved in 83 patients (93%). Procedure associated compli-
cations included 3 myocardial infarction (3%) and 3 emergency bypass (3%)
and 1 elective bypass (1 %). Following the procedure. 77 pts (93%) with 94
les were treated only with anti platelet therapy and no anticoagulation. An-
giographic follow up at 4-6 months was performed on 49 of the eligible 65
lesions (71 %). Baseline. final and follow up angiographic (AG) results are be-
low:
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